July 26, 2021 – Medtronic plc (Dublin, Ireland) announced the launch of the Prevail drug coated balloon (DCB) Catheter in Europe following receipt of CE mark.
The newest coronary DCB on the market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD).
During the catheter-based procedure, the balloon inflates within the artery, while the drug is delivered to the arterial tissue where it is absorbed. The Prevail DCB uses a rapid absorption drug – paclitaxel – to enable treatment of de novo lesions, small vessel disease, and in-stent restenosis (ISR). DCB angioplasty does not require a permanent implant and is often used in cases where the implantation of a drug-eluting stent (DES) is not desirable or is technically challenging.
The Prevail DCB uses PowerTrac, the same technology used in the delivery system for the Medtronic Resolute Onyx DES, to provide superior deliverability and two times more pushability than the previous IN.PACT Falcon technology enabling greater control for tortuous anatomies. In addition, Prevail DCB has a low crossing profile for exceptional crossability, the company says.
The Prevail DCB is the latest addition to the Medtronic coronary portfolio, which also includes the Resolute Onyx DES in sizes ranging from 2.0-5.0 mm, the Euphora semicompliant balloon dilatation catheter, the DxTerity Diagnostic Angiography Catheter line, and the Telescope Guide Extension Catheter.
The Prevail DCB is available for use in Europe and is not approved in the U.S.